Pathophysiology and treatment of fibromyalgia syndrome

Thomas Stratz, Marion Schneider, Thomas O. Joos, Hsin-Yun Hsu, Wolfgang Müller*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Fibromyalgia syndrome is not a diagnosis in itself, but merely represents a set of classification criteria. It is possible to distinguish between different subgroups. Such a distinction can be made on the basis of psychopathological, clinical and laboratory tests. One subgroup reveals elevated level of different cytokines. The treatment of primary fibromyalgia can be optimized by taking these subgroups into consideration since one group responds better to 5-HT3 receptor antagonists, whereas another benefits more from antidepressants and a third group from psychotherapy. In so-called secondary fibromyalgia, 5-HT3 receptor antagonists may be used in the attempt to manage pain that might still persist after treatment of the primary disease.

Original languageEnglish
Pages (from-to)167-170
Number of pages4
JournalCurrent Rheumatology Reviews
Issue number2
StatePublished - May 2007


  • 5-HT3-receptor antagonists
  • Antidepressants
  • Fibromyalgia
  • Psychotherapy
  • Subgroups
  • Treatment
  • Tropisetron


Dive into the research topics of 'Pathophysiology and treatment of fibromyalgia syndrome'. Together they form a unique fingerprint.

Cite this